4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Acumen Pharmaceuticals Inc ABOS
$2.24
▲ +0.22%
(+$0.01)
Open
$2.25
Prev Close
$2.24
Day Range
$2.22 – $2.30
52W Range
$1.22 – $3.60
Market Cap
$161.99M
Beta
0.35
EPS (TTM)
$-1.63
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-01 |
| Shares Out. | 72,230,000 |
| Website | acumenpharm.com/ ↗ |
| Phone | 16173444190 |
| Employees | 61 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$32.7M |
| Free Cash Flow | -$91.8M |
| Total Assets | $116.0M |
| Total Liabilities | $58.7M |
| Equity | $57.3M |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Acumen Pharmaceuticals Inc is a publicly traded company under the ticker symbol ABOS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)